敗血症藥物市場規模、佔有率和成長分析（按藥物類別、病原體類型、治療類型、給藥途徑、最終用戶和地區分類）－2025-2032年產業預測

全球敗血症藥物市場預計到 2024 年將達到 71 億美元，到 2025 年將達到 72.6 億美元，到 2033 年將達到 87.1 億美元，預測期（2026-2033 年）的複合年成長率為 2.3%。

由於加護病房(ICU) 收治人數不斷增加、人口老化以及抗藥性細菌日益流行，全球膿毒症治療市場正經歷顯著成長。對快速起效的非抗生素療法的迫切需求推動了對免疫標靶治療療法和體外療法的投資。創新Start-Ups和醫療技術公司正在開發適用於加護治療環境的先進血液淨化設備和免疫標靶解決方案。政府的大力支持和旨在加速產品開發和臨床試驗的創業投資投資推動了該領域的發展。然而，高昂的研發成本、冗長的監管流程、公眾認知度低、敗血症診斷延遲、複雜的採購流程以及低收入地區醫療基礎設施匱乏等挑戰可能會限制未來的市場成長。

全球膿毒症藥物市場促進因素

全球膿毒症治療市場的主要促進因素之一是全球膿毒症發病率的上升，而這又是由合併糖尿病、癌症和呼吸系統疾病等基礎疾病的患者數量不斷增加所致。隨著醫療保健系統面臨日益複雜的患者群體，醫務人員和公眾對膿毒症及其高死亡率的認知也不斷提高。這種認知的增強不僅推動了對有效治療方案的需求，也促進了創新治療方法的研發。此外，各國政府為改善敗血症管理和診斷而推出的各項措施也持續推動市場成長。

限制全球膿毒症藥物市場的因素

全球敗血症藥物市場的主要限制因素之一是藥物研發和生產高成本。敗血症的複雜性以及對創新治療策略的需求導致了巨額的研發支出。此外，嚴格的監管要求會延緩核准流程，進一步增加製藥公司的成本。這些經濟障礙會抑制對膿毒症相關藥物的投資，限制新治療方法的應用，並延長療效惠及患者的時間。最終，這將阻礙市場成長和有效敗血症治療的普及。

全球膿毒症治療市場趨勢

全球敗血症藥物市場正呈現顯著成長趨勢，這主要得益於人們對敗血症及其對全球醫療系統造成的毀滅性影響的認知不斷提高。隨著醫療機構將早期診斷和有效治療通訊協定置於優先地位，單株抗體、免疫療法和新型抗菌藥物等創新治療方法應運而生。此外，基於生物標記的診斷技術和個人化醫療的進步也正在改善治療效果。醫療政策對膿毒症管理的日益重視以及製藥公司在研發方面的投入，進一步推動了市場成長。隨著對加強預防措施和改善患者預後的日益關注，膿毒症藥物的未來前景一片光明。

目錄

介紹

• 調查目標
• 市場定義和範圍

調查方法

• 調查過程
• 二手資料和一手資料方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 主要市場亮點
• 細分市場概覽
• 競賽概況

市場動態與展望

• 總體經濟指標
• 促進因素和機遇
• 限制與挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場考察

• 關鍵成功因素
• 影響市場的因素
• 關鍵投資機會
• 生態系測繪
• 市場吸引力指數（2025）
• PESTEL 分析
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 技術評估
• 技術評估
• 監管環境

全球膿毒症藥物市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 抗生素
• 抗真菌藥物
• 皮質類固醇
• 免疫調節劑
• 血管加壓藥
• 止痛藥和鎮靜劑
• 抗凝血劑

全球敗血症藥物市場規模（按病原體類型和複合年成長率分類）（2026-2033 年）

• 細菌性敗血症
• 黴菌性敗血症
• 病毒性敗血症

全球敗血症治療市場規模（依療法分類）及複合年成長率（2026-2033 年）

• 液體復甦
• 血液淨化技術
• 症狀支持治療
• 標靶免疫療法

全球敗血症藥物市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 靜脈注射
• 口服
• 其他

全球膿毒症治療市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 門診手術中心
• 診所
• 研究和學術機構

全球敗血症治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Johnson & Johnson
• AbbVie Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Bayer AG
• Baxter International Inc.
• Becton, Dickinson and Company（BD）
• Thermo Fisher Scientific Inc.
• CSL Behring
• Grifols SA
• BioMerieux SA
• Bio-Rad Laboratories
• Shionogi & Co., Ltd.
• Sandoz（Novartis division）
• Takeda Pharmaceutical Company Limited

結論與建議

Global Sepsis Therapeutics Market size was valued at USD 7.1 billion in 2024 and is poised to grow from USD 7.26 billion in 2025 to USD 8.71 billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global sepsis therapeutics market is experiencing significant growth driven by rising ICU admissions, an aging population, and an increasing prevalence of drug-resistant organisms. The urgent need for rapid-acting, non-antibiotic therapies is propelling investments in immune-targeted and extracorporeal treatments. Innovative startups and medtech companies are developing advanced blood purification devices and immune-targeted solutions suitable for critical care settings. This sector is bolstered by considerable government support and venture capital investment aimed at facilitating accelerated product development and clinical trials. However, challenges such as high development costs, lengthy regulatory processes, limited awareness, late diagnosis of sepsis, complex procurement procedures, and inadequate healthcare infrastructure in lower-income regions may restrain market growth moving forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sepsis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sepsis Therapeutics Market Segments Analysis

Global Sepsis Therapeutics Market is segmented by Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Antibiotics, Antifungals, Corticosteroids, Immunomodulators, Vasopressors, Analgesics and Sedatives and Anticoagulants. Based on Pathogen Type, the market is segmented into Bacterial Sepsis, Fungal Sepsis and Viral Sepsis. Based on Treatment Type, the market is segmented into Fluid Resuscitation, Blood Purification Techniques, Symptomatic and Supportive Care and Targeted Immunotherapy. Based on Route of Administration, the market is segmented into Intravenous, Oral and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Clinics and Research and Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sepsis Therapeutics Market

One of the key market drivers for the global sepsis therapeutics market is the rising incidence of sepsis globally, fueled by an increasing number of patients with comorbidities such as diabetes, cancer, and respiratory diseases. As healthcare systems grapple with the rising complexity of patient profiles, awareness of sepsis and its high mortality rates has intensified among both medical professionals and the general public. This heightened awareness not only drives demand for effective therapeutic solutions but also stimulates research and development efforts towards innovative treatments. Furthermore, government initiatives aimed at improving sepsis management and diagnosis continue to bolster market growth.

Restraints in the Global Sepsis Therapeutics Market

One of the key market restraints for the global sepsis therapeutics market is the high cost associated with drug development and production. The complexity of sepsis as a condition, along with the need for innovative treatment strategies, results in significant research and development expenses. Moreover, stringent regulatory requirements can delay the approval process, further increasing costs for pharmaceutical companies. These financial barriers can deter investment in sepsis-related therapeutics, limiting the availability of new treatments and prolonging the time it takes for advancements to reach patients. This ultimately hampers market growth and accessibility of effective sepsis therapies.

Market Trends of the Global Sepsis Therapeutics Market

The Global Sepsis Therapeutics market is witnessing a significant upward trend, driven by rising awareness about sepsis and its devastating impact on health systems worldwide. As healthcare providers increasingly prioritize early diagnosis and effective treatment protocols, innovative therapies are emerging, including monoclonal antibodies, immunotherapies, and novel antimicrobial agents. Additionally, advancements in biomarker-based diagnostics and personalized medicine are enhancing treatment efficacy. The growing focus on sepsis management within healthcare policies and investments in research and development by pharmaceutical companies are further propelling market growth. With a larger emphasis on preventative measures and improved patient outcomes, the future of sepsis therapeutics looks promising.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment
• Technology Assessment
• Regulatory Landscape

Global Sepsis Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibiotics
• Antifungals
• Corticosteroids
• Immunomodulators
• Vasopressors
• Analgesics and Sedatives
• Anticoagulants

Global Sepsis Therapeutics Market Size by Pathogen Type & CAGR (2026-2033)

• Market Overview
• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis

Global Sepsis Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Fluid Resuscitation
• Blood Purification Techniques
• Symptomatic and Supportive Care
• Targeted Immunotherapy

Global Sepsis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Oral
• Others

Global Sepsis Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Research and Academic Institutes

Global Sepsis Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis division)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations